NeoGenomics To Present New Research Demonstrating High Concordance Between RaDaR ST And RaDaR 1.0 Assays For Detecting MRD In Solid Tumors, At ISLB Annual Congress 2025

Author: Benzinga Newsdesk | October 30, 2025 12:53pm

Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. NeoGenomics will also present on the progress of its NextGen (whole genome-based) MRD research program, as well as three additional posters highlighting the company's work in liquid biopsy and genomic profiling across solid tumor types.

The bridging study, "Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types" (PP.41), evaluated matched samples from 166 patients representing 15 solid tumor types. RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. This study provides analytical confirmation that RaDaR ST maintains the performance of RaDaR 1.0, supporting continuity in MRD assessment as the platform is updated. RaDaR ST is currently covered by Medicare for HR+/HER2- breast cancer (>5 years after diagnosis, recurrence monitoring) and HPV- head and neck carcinoma (adjuvant and recurrence monitoring) and has demonstrated utility across multiple tumor types.

In addition to the RaDaR ST bridging study, NeoGenomics will present four other posters at ISLB:

• Performance Characterization of a Novel Whole Genome Sequencing Informed MRD Assay (PP.15), evaluating a whole genome-informed, tumor-specific approach to detect ctDNA at very low levels in solid tumors.
• Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels (PP.74), analyzing genomic features of early-stage lung cancers and investigating the relationship between tumor genomics, ctDNA detectability, and clinical outcomes in these patients.
• Validation of NEO │ PanTracer LBx, a Liquid Biopsy Precision Oncology Pan-Solid Tumor Comprehensive Genomic Profiling Assay (PP.05), presenting analytical and clinical validation findings for therapy selection using liquid biopsy.
• Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay (PP.04), assessing liquid biopsy-based comprehensive genomic profiling to detect actionable variants and support treatment decisions in late-stage cancers.

These presentations contribute to NeoGenomics' growing body of research in liquid biopsy for MRD detection and genomic profiling. The findings reinforce the company's strategy to advance next-generation molecular testing platforms and expand the role of ctDNA in clinical research and patient management.

Posted In: NEO